| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/01/2005 | WO2004096195A8 Use of ppar-gamma agonists as anti-infective agents |
| 09/01/2005 | WO2004089353A8 Methods for treatment of parkinson's disease |
| 09/01/2005 | WO2004082600A3 Method and system for administering a drug |
| 09/01/2005 | WO2004078133A8 Antineoplastic combinations comprising a rapamycin derivative and an aromatase inhibitor |
| 09/01/2005 | WO2004076450A8 Pyrazolopyridine derivates |
| 09/01/2005 | WO2004063388A3 Hydroxyphenyl cross-linked macromolecular network and applications thereof |
| 09/01/2005 | WO2004057979A3 Dietary foodstuff for positively influencing cardiovascular health containing a carob product and an omega-3 fatty acid |
| 09/01/2005 | WO2004024076A8 Novel compositions and methods for the treatment of immune related diseases |
| 09/01/2005 | US20050192664 Controlled release endoprosthetic device |
| 09/01/2005 | US20050192445 Semi-synthesis of taxane intermediates and aziridine analogues and their conversion to paclitaxel and docetaxel |
| 09/01/2005 | US20050192432 From mutated Streptomyces argillaceous; antitumor agents; hypercalcemia; hypercalcuria |
| 09/01/2005 | US20050192361 Treating with beta lapachone (3,4-dihydro-2, 2-dimethyl-2H-naphtho [1,2-b]pyran-5, 6-dione) |
| 09/01/2005 | US20050192360 Method of treatment of pancreatic cancer |
| 09/01/2005 | US20050192358 carbocyclic imidodisulfamide compounds; preferably but not limited to infections caused by orthopox viruses |
| 09/01/2005 | US20050192357 Applying a prostaglandin D receptor selective agonist, e.g., a 1R,2R,3R,5R)-5-halo-2-[(1E,3S)-3-cycloalkyl-3-hydroxy-1-propenyl]-3-hydroxycyclopentyl]-(5Z)-5-alkenoic acid; in particular treating senile xeroderma. |
| 09/01/2005 | US20050192356 Synergistic anti-inflammatory pharmaceutical compositions and methods of use |
| 09/01/2005 | US20050192355 Compositions of non-steroidal anti-inflammatory drugs and decongestants or anti-histamines |
| 09/01/2005 | US20050192353 Treating or preventing restless legs syndrome using prodrugs of GABA analogs |
| 09/01/2005 | US20050192352 Method for decreasing cartilage damage in dogs |
| 09/01/2005 | US20050192351 reacting 3-methyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4-pentadienyl)-triphenylphosphonium chloride with 5-hydroxy-4-methyl-2(5H)-furanone, then isomerizing in ethanol solvent/potassium hydroxide base in presence of palladium nitrate catalyst |
| 09/01/2005 | US20050192350 Aspirin-triggered lipoxins as modulators of diseases associated with polymorphoneutrophil inflammation; antiinflammatory agents |
| 09/01/2005 | US20050192349 Stimulating cells in culture medium causing secretion; harvesting after induction of differentiation; isolating high affinity, endogenous, neutral lipophilic compounds; reducing insulin resistance |
| 09/01/2005 | US20050192348 Methods and products which utilize N-acyl-L-aspartic acid |
| 09/01/2005 | US20050192345 Of Monohydrate of 3-(1-(5-methylfuran-2-yl)propylamino)-4-(2-hydroxy-3-(dimethylaminocarbonyl)phenylamino)-3-cyclobutene-1,2-dione; treating pain, autoimmune diseases, cancer, transplant rejection |
| 09/01/2005 | US20050192344 Treatment or prophylaxis of migraine or headache disorders using citalopram, escitalopram or citalopram metabolites |
| 09/01/2005 | US20050192343 Nerve growth factor activity potentiating agents |
| 09/01/2005 | US20050192342 Chroman-derived anti-androgens for treatment of androgen-mediated disorders |
| 09/01/2005 | US20050192341 Use of partially saturated dibenzo(b,d)pyran compounds such as dexanabinol (1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol); neuroprotectant and antiinflammatory effects; mild cognitive impairment to chronic neurodegenerative disorders |
| 09/01/2005 | US20050192340 Simvastatin formulations and methods of making same |
| 09/01/2005 | US20050192336 Treatment may include administration of a second active agent, including but not limited to, an anti-inflammatory agent, an immnunosuppressant, mycophenolate mofetil, a biologic agent, or a Cox-2 inhibitor |
| 09/01/2005 | US20050192335 Acyloxypyrrolidine derivatives, preparation thereof and application thereof in therapeutic |
| 09/01/2005 | US20050192334 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands |
| 09/01/2005 | US20050192332 Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same |
| 09/01/2005 | US20050192331 Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| 09/01/2005 | US20050192329 Treating agent for irritable bowel syndrome |
| 09/01/2005 | US20050192328 Compounds and methods for use thereof in the treatment of viral infections |
| 09/01/2005 | US20050192327 Myocardial infarction or its recurrence is treated with telmisartan an ACE inhibitor |
| 09/01/2005 | US20050192326 Treating stroke or reccurence with an ACE inhibitor selected from quinapril, captropril, lisinopril, perindopril, trandolapril, enalapril, moexipril, fosinopril, ramipril, cilazapril, imidapril, spirapril, temocapril, benazepril, alacepril, ceronapril, delapril, moveltipril and trandolapril |
| 09/01/2005 | US20050192325 For therapy of bacterial infections; such as N-[((5S)-3-{3-fluoro-4-[exo-(1R,5S)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide |
| 09/01/2005 | US20050192324 Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof |
| 09/01/2005 | US20050192322 Calcium blockers to treat proliferative vitreoretinopathy |
| 09/01/2005 | US20050192321 Multiple sclerosis therapy by administering 5 and less than 18 mg of 4-aminopyridine per dose and 2,3-diaminopyridine, and 2,4-diaminopyridinein at least two doses per day; inhibit central nervous system side effects |
| 09/01/2005 | US20050192320 (2-Carboxamido)(3-amino)thiophene compounds |
| 09/01/2005 | US20050192318 5-[4-Methylsulfonyloxy-2-(S)-(3,4-dichlorophenyl)butyl]-10-cyano-3-(R)-methyl-6-oxo-3,4,5,6-tetrahydro-2H-benzo[b][1,5]oxazocine as antidepressant |
| 09/01/2005 | US20050192317 Novel diamines having a casr modulating activity |
| 09/01/2005 | US20050192315 New compositions containing quinoline compounds |
| 09/01/2005 | US20050192314 Use of urea derivatives of isoxazoles; c-kit kinase inhibitors; anticancer agents; leukemias such as acute myelogenous leukemia (AML), and chronic myelogenous leukemias (CMLs) |
| 09/01/2005 | US20050192313 Thio substituted with a hetero multiring group; sleepiness, promotion of wakefulness, Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain, attention deficit hyperactivity disorder |
| 09/01/2005 | US20050192312 Naphthalimide dosing by N-acetyl transferase genotyping |
| 09/01/2005 | US20050192310 Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 |
| 09/01/2005 | US20050192309 Method of preventing abuse of opioid dosage forms |
| 09/01/2005 | US20050192308 N-but-E-enyl norbuprenorphine and methods of use |
| 09/01/2005 | US20050192307 Benzimidazolone compounds |
| 09/01/2005 | US20050192306 Pyrimidine derivatives as selective inhibitors of COX-2 |
| 09/01/2005 | US20050192304 Rho-kinase inhibitors |
| 09/01/2005 | US20050192303 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds |
| 09/01/2005 | US20050192302 3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors |
| 09/01/2005 | US20050192301 Use to prepare antiproliferative anticancer agents such as 2-(p-(4-methylpiperazino)-3-methylphenylamino)-4-(2-formamidocyclopentylamino)-5-fluoro-pyrimidine |
| 09/01/2005 | US20050192300 Pyrimidine compounds |
| 09/01/2005 | US20050192299 Method of treating or preventing hepatitis B virus |
| 09/01/2005 | US20050192297 melanocortin-4 receptor (MC4-R) agonists; antidiabetic agents; non-insulin dependent diabetes; obesity |
| 09/01/2005 | US20050192295 6-Chloro-N-cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-(3-methylphenyl)pyrazolo[1,5- alpha ]pyridin-7-amine or salt; treatment of a herpes viral infection in human |
| 09/01/2005 | US20050192294 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes |
| 09/01/2005 | US20050192293 Vanilloid receptor VR1 modulators; pain, inflammation, traumatic injury, autoimmune disease; compounds are pyridine subsituted at 2 position with an amido-, sulfoamido- or thioamide-substituted (N-hetero)aryl ring |
| 09/01/2005 | US20050192290 Antihistamine is selected from ceterizine, fexofenadine, loratadine, and desloratadine or together with a stimulant methylphenidate to down regulate neurotrophic factor selected from nerve growth factor (NGF) and CD40, to treat ADHD, anxiety, depression, and autism |
| 09/01/2005 | US20050192288 Benzofuran-2-yl-carbonyl- and indol-2-yl-carbonyl-trans-2,5-dimethyl-piperazine derivatives; rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, asthma; inhibit the interaction between inflammatory chemokines and their receptor |
| 09/01/2005 | US20050192287 Substituted benzazoles and methods of their use as inhibitors of Raf kinase |
| 09/01/2005 | US20050192286 Ligands of melanocortin receptors and compositions and methods related thereto |
| 09/01/2005 | US20050192285 Method of treatment |
| 09/01/2005 | US20050192284 Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processed for its manufacture and its use |
| 09/01/2005 | US20050192283 Fused-aryl and heteroaryl derivatives and methods of their use |
| 09/01/2005 | US20050192282 Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma |
| 09/01/2005 | US20050192281 Nitrone compounds, prodrugs and pharmaceuticals compositons of the same to treat human disorders |
| 09/01/2005 | US20050192279 Pyridazinones as antagonists of alpha4 integrins |
| 09/01/2005 | US20050192276 modulators of monocyte chemotactic proteins MCP-1 receptor; inflammatory diseases such as asthma and allergies, autoimmune diseases such as rheumatoid arthritis and atherosclerosis |
| 09/01/2005 | US20050192274 Combinations of drugs for the treatment of neoplastic disorders |
| 09/01/2005 | US20050192273 Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist |
| 09/01/2005 | US20050192272 Substituted benzodiazepines as inhibitors of the chemokine receptor CXCR4 |
| 09/01/2005 | US20050192271 Patient evaluation step: a complete physical/psychological examination, a CIWA assessment, determination of required medications; administering Flumazenil as selective chloride channel modulator, monitoring, prescribing fortified vitamin b, hydroxyzine, or gabapentin as other therapeutical agent |
| 09/01/2005 | US20050192270 Using synergistic mixture of serotonin receptor antagonist and noradrenaline reuptake inhiitor; diarrhea, consti[ation, gastrointestinal disorders |
| 09/01/2005 | US20050192269 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
| 09/01/2005 | US20050192268 Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| 09/01/2005 | US20050192267 Use of targeted oxidative therapeutic formulation in treatment of viral diseases |
| 09/01/2005 | US20050192266 Including vanadocene dihalides, bis(methylcyclopentadienyl), vanadocene diazide, vanadocene dicyanide, vanadocene dioxycyanate, vanadocene dithiocyanate, vanadocene diselenocyanate, vanadocene ditriflate, vanadocene monochloro oxycyanate, vanadocene monochloro acetonitrilo tetrachloro ferrate |
| 09/01/2005 | US20050192265 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
| 09/01/2005 | US20050192264 Crystal or crystalline composite; crystal size and distribution of which are determinable and selectable; anti-inflammatory steroid is a 11-substituted-16 alpha ,17 alpha -substituted methylenedioxy steroid (triamcinolone acetonide); treat inflammatory eye conditions |
| 09/01/2005 | US20050192263 3,15-substituted estrone compounds; treatment of steroid hormone dependent diseases such as breast cancer, colon cancer, endometriosis, benign prostatic hyperplasia |
| 09/01/2005 | US20050192262 Steroid derivatives of 5-androstene-, 5-pregnenolone or corresponding saturated derivatives, for example 5-androstene-3beta,7beta,17alpha-triol; interrupting disturbances in Wnt-signaling, such as cell-cycle arrest in G1-phase, and/or providing an angiostatic effect; benign and/or malignant tumors |
| 09/01/2005 | US20050192261 Methods and reagents for the treatment of immunoinflammatory disorders |
| 09/01/2005 | US20050192260 Pharmaceutical composition |
| 09/01/2005 | US20050192259 A sustained release formulation of an aldosterone antagonist orally administered about 6-12 hours prior to the acrophase to provide a profile of plasma drug concentration corresponding to the diurnal cycle of plasma aldosterone concentration; hypotensive agents; circadi rhythm; cardiovascular disorders |
| 09/01/2005 | US20050192257 Evaluating a patient's risk of increased intraocular pressure by intraocularly administering a triamcinolone dosage of 50-800 mu g and determining if a postadministration intraocular pressure is > 5 mm Hg greater than a preadministration intraocular pressure; also contain an angiogenisis inhibiters |
| 09/01/2005 | US20050192256 Reducing the frequency of hospital admissions and the length of hospital stays for a mammal by administering orally or intravenous injection a Vitamin D compound, e.g. calcitriol, a Vitamin D analog, a Vitamin D metabolite, Vitamin D2 and Vitamin D3 or paricalcitol; urogenital disorders; kidney failure |
| 09/01/2005 | US20050192255 Sustained release composition for cardio-, cerebro- and peripheral vascular diseases of a Vitamin D receptor activators, e.g., paricalcitol, calcitriol, doxercalciferol, and optionally an angiotensin converting enzyme inhibitor, an angiotensin II receptor I blocker, an aldosterone blocker; no side effect |
| 09/01/2005 | US20050192254 Administering for Class III heart failure or acute heart failure and not conjestive heart failure a dose of a nitroxyl donating compound, where it is not Angeli's salt and a potassium-channel activator is not present, to increase myocardial contractility; also receiving adrenergic blocking agent |
| 09/01/2005 | US20050192253 For treating cancer, cardiovascular, sexual and immune disorders; 3a alpha ,4 beta ,5 alpha ,7 beta ,7a alpha )-4-(Octahydro-5- ethylsulfonamido-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2- (trifluoromethyl)benzonitrile |
| 09/01/2005 | US20050192252 Administering 30 mg of enoxaparin sodium by subcutaneous injection once daily, beginning approximately two hours prior to abdominal surgery for the prevention of thrombotic episodes in a postoperative human |
| 09/01/2005 | US20050192251 Water soluble bioactive fraction isolated from gum resin exudate of Boswellia serrata, process for isolation thereof composition containing said fraction and use thereof |
| 09/01/2005 | US20050192250 Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
| 09/01/2005 | US20050192249 Room temperature stable agarose solutions |